Ocugen Inc said on Friday U.S. regulators have declined to issue an emergency use authorization (EUA) for Covaxin, the C-19 vaccine developed by its Indian partner Bharat Biotech, for use in individuals aged 2 to 18 years.

Shares of Ocugen slumped 30% premarket on the news.

Ocugen said it intends to continue working with the U.S. Food and Drug Administration (USFDA) to evaluate the process for getting an EUA for pediatric use of Covaxin.

Click for more on USFDA

Ocugen had entered into a deal with vaccine maker Bharat Biotech in late 2020, under which it would develop, supply, and commercialize Covaxin for the U.S. market.

Covaxin, which is not cleared for any age group in the United States, is one of the two most widely used C-19 vaccines in India and also has an emergency use listing from the World Health Organization.

NPPA cancels study access of medicine at affordable prices

WHO updates its treatment guidelines to include Molnupiravir

USFDA gives nod to Lupin for generic Jublia topical solution

Govt listed 213 drugs for which procurement agencies could not find local manufacturers

USFDA gives nod to Lupin for Sevelamer Hydrochloride Tablets, 800 mg

USFDA declines to approve Gilead’s HIV drug on this concern

Why these Pharma Companies are realigning their India operations

USFDA approves this drug for bone marrow cancer treatment

NDPS Exporters and Importers to register with ICEGATE portal: CBN

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/03/05/usfda-declines-pediatric-eua-for-vaccine-covaxin/